Thursday, 15 April 2004
|
||
| Organisers | C.J.M. Lips (Utrecht, The Netherlands) Th.P. Links (Groningen, The Netherlands) |
|
| Sponsors | Ferring (The Netherlands) Genzyme (The Netherlands) Novartis Pharma BV (The Netherlands) Novo Nordisk Pharma BV (The Netherlands) |
|
Familial endocrine syndromes and oncological endocrinology |
||
| Session I | Pheochromocytoma |
Thursday morning |
| Chairs | C.J.M. Lips (Utrecht, The Netherlands) Th.P. Links (Groningen, The Netherlands) |
Abstract number |
| 08.30 – 09.10 | Recent advances in genomics, proteomics, and localization of pheochromocytoma K. Pacak (Bethesda, USA) |
|
| 09.10 – 09.40 | Pheochromocytoma: Clinical consequences and the optimal biochemical diagnostic strategy J.W.M. Lenders (Nijmegen, The Netherlands) |
75 |
| 09.40 – 10.05 | Germline mutations in the SDHD gene and the clinical expression of paragangliomas C.J. Cornelisse (Leiden, The Netherlands) |
76 |
| 10.00 – 11.15 | coffee break + plenary lecture | |
| 11.30 – 11.55 | Genotype-phenotype correlations in phaeochromocytoma R.R. de Krijger (Rotterdam, The Netherlands) |
77 |
| 11.55 – 12.10 | Iodine-123-Metaiodobenzylguanidine scintigraphy in localising functional paragangliomas, a pooled analysis A.N.A. van der Horst-Schrivers, P.L. Jager, I.P. Kema, J.P. Schouten, and T.P. Links (Groningen, The Netherlands) |
78 |
| 12.10 – 12.25 | Treatment of malignant pheochromocytoma M. Lam (Utrecht, The Netherlands) |
|
| 12.25 – 12.40 | Pheochromocytoma in familial syndromes E. de Koning (Utrecht, The Netherlands) |
|
| 12.40 – 13.00 | discussion / end of session | |
| 13.00 – 15.00 | lunch / poster viewing / exhibition + plenary lecture | |
| Session II | Carcinoid | Thursday afternoon |
| Chairs | C.J.M. Lips (Utrecht, The Netherlands) Th.P. Links (Groningen, The Netherlands) |
abstract number |
| 15.00 – 15.30 | Clinical chemistry of carcinoid tumours I.P. Kema (Groningen, The Netherlands) |
|
| 15.30 – 16.00 | Diagnostic and treatment of carcinoid tumours B. Taal (Amsterdam, The Netherlands) |
|
| 16.00 – 16.30 | coffee break | |
| 16.30 – 16.55 | Complications of carcinoid tumours E.G.E. de Vries / A.N.A. v.d. Horst-Schrivers (Groningen, The Netherlands) |
|
| 16.55 – 17.20 | Diagnosis and treatment of other neuro-endocrine tumours W.W. de Herder (Rotterdam, The Netherlands) |
|
| 17.20 – 17.35 | The role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease J.M. Zuetenhorst, C.M. Korse, J.M.G. Bonfrer, R.H. Bakker, and B.G. Taal (Amsterdam, The Netherlands) |
79 |
| 17.35 – 17.50 | Early experience of F-DOPA PET in carcinoids P.L. Jager (Groningen, The Netherlands) |
|
| 17.50 – 18.00 | Carcinoid tumours in MEN 1 K. Dreyerink (Utrecht, The Netherlands) |
|
| 18.00 | end of session | |
| Session III | Differentiated thyroid cancer | Friday morning |
| Chairs | C.J.M. Lips (Utrecht, The Netherlands) Th.P. Links (Groningen, The Netherlands) |
Abstract number |
| 08.30 – 9.00 | Treatment of atypical epithelial thyroid carcinoma: discrepancy between iodine uptake and thyroglobulin levels F. Pacini (Siena, Italy) |
80 |
| 09.00 – 09.20 | Novel therapies in differentiated thyroid carcinoma J.W.A. Smit (Leiden, The Netherlands) |
81 |
| 09.20 – 09.40 | Role of nuclear medicine in differentiated thyroid carcinoma J.M.H.de Klerk (Utrecht, The Netherlands) |
82 |
| 09.40 – 10.05 | Mutation dependent RET signaling in medullary thyroid carcinoma R.M.W. Hofstra (Groningen, The Netherlands) |
|
| 10.00 – 11.15 | coffee break + plenary lecture | |
| 11.30 – 11.55 | Multistep carcinogenesis in medullary thyroid carcinoma D.S. Acton (Utrecht, The Netherlands) |
83 |
| 11.55 – 12.15 | Medullary Thyroid Carcinoma: strategies for treatment and follow-up C.J. Lips, D.S. Acton, J.W. Höppener, G.H. Donker, E.G. Lentjes, and B.A. Zonnenberg (Utrecht, The Netherlands) |
84 |
| 12.15 – 12.30 | Inhibition of RET-mediated medullary thyroid carcinoma cell growth by imatinib J.W.B. de Groot, I. Plaza Menacho, B.J.L. Eggen, J.Th.M. Plukker, R.M.W. Hofstra, and Th.P. Links (Groningen, The Netherlands) |
85 |
| 12.30 – 12.45 | Clinical experience with STI 571 in medullary thyroid carcinoma B. Zonnenberg (Utrecht, The Netherlands) |
|
| 12.45 – 13.00 | Clinical use of rhTSH in differentiated thyroid carcinoma Th.P. Links (Groningen, The Netherlands) |
|
| 13.00 | end of workshop | |
Posters |
||
| Intermittent androgen suppression in patients with prostate cancer R. Kadiev (Stavropol, Russia) |
86 | |
| Modulation of biodistribution of 131I-MIBG after Interferon and unlabeled MIBG in metastatic carcinoid J.M. Zuetenhorst, R.A. Valdes Olmos, M. Muller, C.A. Hoefnagel, and B.G. Taal (Amsterdam, The Netherlands) |
87 | |
